Related Experiment Videos
[Immunosuppressive therapy of polymyositis]
Psychiatrie, Neurologie Und Medizinische Psychologie. Beihefte
|January 1, 1975
Summary
Polymyositis is classified as an autoimmunopathy, supporting immunosuppressive therapy. Monitoring erythrocyte sedimentation rate and blood count aids optimal treatment effectiveness.
Area of Science:
- Immunology
- Rheumatology
Background:
- Polymyositis is classified as an autoimmune disease.
- Experimental findings support this classification.
Observation:
- Glucocorticoids are significant in polymyositis treatment.
- Experience with cytostatics (Azathioprine, Methotrexate, Cyclophosphamide) reviewed.
- Two cases of polymyositis treated with immunosuppressants.
Findings:
- Erythrocyte sedimentation rate, blood count, fibrinogen, and lymphocyte transformation tests reliably measure immunosuppressive effect.
- Immunosuppressive therapy is justified based on autoimmunopathy classification.
Implications:
- This study provides a theoretical basis for immunosuppressive therapy in polymyositis.
- Monitoring key biomarkers is crucial for optimizing immunosuppressive therapy.
- Caution advised regarding mutagenic, teratogenic, and oncogenic risks of cytostatic agents.